1. Home
  2. VCEL vs JANX Comparison

VCEL vs JANX Comparison

Compare VCEL & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$39.00

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$13.28

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCEL
JANX
Founded
1989
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
VCEL
JANX
Price
$39.00
$13.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
12
Target Price
$57.50
$60.27
AVG Volume (30 Days)
575.4K
2.3M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
236.54
N/A
EPS
0.25
N/A
Revenue
$258,716,999.00
$10,000,000.00
Revenue This Year
$17.86
N/A
Revenue Next Year
$18.55
N/A
P/E Ratio
$150.36
N/A
Revenue Growth
14.05
N/A
52 Week Low
$29.24
$13.28
52 Week High
$63.00
$61.59

Technical Indicators

Market Signals
Indicator
VCEL
JANX
Relative Strength Index (RSI) 58.62 26.28
Support Level $35.33 $13.82
Resistance Level $38.15 $14.49
Average True Range (ATR) 1.43 0.47
MACD 0.12 0.36
Stochastic Oscillator 99.29 1.56

Price Performance

Historical Comparison
VCEL
JANX

About VCEL Vericel Corporation

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: